Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability

  • Joshua Burns, Robert Ouvrier, Tim Estilow, Rosemary Shy, Matilde Laurá, Julie F. Pallant, Monkol Lek, Francesco Muntoni, Mary M. Reilly, Davide Pareyson, Gyula Acsadi, Michael E. Shy, Richard S. Finkel
  • Annals of Neurology, April 2012, Wiley
  • DOI: 10.1002/ana.23572

Validation of the CMTPedS

What is it about?

The CMTPedS is a well-tolerated psychometrically robust 11-item clinical outcome measure assessing fine and gross motor function, strength, sensation and balance in children and adolescents aged 3-20 years. The CMTPedS has been subjected to classical test theory (item, reliability and factor analysis) and item response theory (Rasch modelling) to ensure it can reliably capture changes in disability over time.

Why is it important?

The CMTPedS is the only disease-specific scoring system available for children with Charcot-Marie-Tooth disease.

Perspectives

Joshua Burns
University of Sydney

The CMTPedS is a linearly-weighted and responsive Clinical Outcome Assessment used in >200 hospitals and universities internationally to standardise the assessment of Charcot-Marie-Tooth disease.

Read Publication

http://dx.doi.org/10.1002/ana.23572

The following have contributed to this page: Joshua Burns